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The CC chemokine receptor 5 (CCR5) has been shown to be important in the recruitment of T-helper cells to the synovium,
where they accumulate, drive the inflammatory process and the consequent synovitis and joint destruction. A 32 base-pair
insertion/deletion variant (CCR5D32) within the gene leads to a frame shift and a nonfunctional receptor. CCR5D32 has been
investigated for its association with juvenile idiopathic arthritis (JIA), with conflicting results. The aim of this study was to
investigate whether CCR5D32 is associated with JIA in an UK population. CCR5D32 was genotyped in JIA cases (n¼1054)
and healthy controls (n¼3129) and genotype and allele frequencies were compared. A meta-analysis of our study combined
with previously published studies was performed. CCR5D32 was significantly associated with protection from developing JIA,
in this UK data set (Ptrend¼0.006, odds ratio (OR) 0.79 95% confidence interval (95% CI): 0.66–0.94). The meta-analysis
of all published case–control association studies confirmed the protective association with JIA (P¼0.001 OR 0.82 95%
CI: 0.73–0.93). CCR5D32 is a functional variant determining the number of receptors on the surface of T cells, and it
is hypothesized that the level of CCR5 expression could influence the migration of proinflammatory T cells into the synovium
and thus susceptibility to JIA.
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Introduction
Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease of childhood. It is defined as
chronic inflammation of the synovial joints, with
unknown etiology, which starts before the age of 16
years and persists for at least 6 weeks. There is a wealth
of evidence to suggest that the pathogenesis is largely
driven by Tcells.
1 It has been shown that there is a strong
bias in the overall T-helper (Th) 1 cytokine profile of
synovial fluid (SF) T cells compared with peripheral
blood T cells from patients with either oligoarticular or
polyarticular JIA, and it is proposed that this polarization
may be caused by selective recruitment by chemokine
receptor expression.
2 CC chemokine receptor 5 (CCR5) is
predominantly found on monocytes and T cells, particu-
larly of the Th1 phenotype.
3 Its function is in the
recruitment of these Th1 T cells to the synovium, where
they accumulate and produce proinflammatory cyto-
kines, such as interleukin-2 (IL2) and interferon-g (which
drives the inflammatory process and the consequent
synovitis and joint destruction). CCR5 binds a number of
proinflammatory chemokines, including CC chemokines,
such as CCL3 (also known as macrophage inflammatory
protein 1a), CCL4 (macrophage inflammatory protein b)
and CCL5 (also known as regulated on activation,
normal T-cell expressed and secreted).
4 These chemo-
kines have been found at high levels in the SF of patients
with adult rheumatoid arthritis (RA),
5 suggesting that
CCR5þ T cells selectively accumulate in the SF in
response to the presence of these chemokines. Further-
more, it has also been noted that the cell-surface CCR5
density determines the intensity of T-cell migration
toward RA synoviocytes and also their stimulation by
CCL5.
6 Thus, the level of CCR5 expression could favor
the inflammatory effect of intra-articular T cells by
facilitating their recruitment and increasing their res-
ponse to chemokines. Therefore, the density of CCR5 on
cells may be predictive of disease severity.
The CCR5 gene on chromosome 3p21.3 contains a 32
base-pair insertion/deletion variant (CCR5D32), which
leads to a frame shift and a nonfunctional receptor.
Homozygosity for CCR5D32 results in a complete lack of
surface expression of CCR5, whereas heterozygotes
express low densities of cell-surface CCR5 compared
with individuals homozygous for the wild-type CCR5
gene.
7 The polymorphism has been extensively studied
in RA with conflicting evidence for a protective associa-
tion of the CCR5D32 polymorphism.
8–12 However, a large
meta-analysis of five case–control association studies
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and RA (odds ratio (OR) 0.65 95% confidence interval
(95% CI): 0.55–0.77, Po0.0001).
13 In JIA, again, the results
are conflicting; one study reported that the CCR5D32
variant was protectively associated with JIA;
14 another
described no association;
15 and a third found that the
CCR5D32 variant was associated with JIA susceptibility.
16
The aim of this study was to investigate whether
CCR5D32 is associated with JIA in an UK population
and to combine the results with those obtained in
previous studies by meta-analysis.
Results
Genotype counts conformed to Hardy–Weinberg expec-
tations (P40.05) in the control cohort. After quality
control, 987 JIA samples and 3121 control samples were
available for analysis. We found that the CCR5D32
variant was significantly associated with protection from
developing JIA (Ptrend¼0.006, OR 0.79 95% CI: 0.66–0.94)
(Table 1).
Interestingly, the strongest protective effect was found
in the rheumatoid factor-positive polyarthritis subtype
(OR 0.41 95% CI: 0.18–0.93) (Table 2); however, there was
no significant difference in allele frequencies across all
the subtypes, suggesting that no subtype-specific asso-
ciations exist.
To perform the meta-analysis, allele and genotype data
from previous studies in JIA were collated (Table 3).
Three previous studies were identified from literature
searches: one from the United States,
14 the second, a
study of Norwegian JIA cases and controls
15 and finally
a study of Brazilian JIA cases and controls.
16 The US
study was a family-based association analysis; hence for
the meta-analysis, data collected from the parents and
unaffected siblings were used as control data. Studies
from the Unites States and Norway reported very similar
control allele frequencies (10–11%). However, control
allele frequencies in the Brazilian study by Scheibel et al.
were very different (3.8%). This study was relatively
small and reported association of the CCR5D32 variant
with JIA susceptibility. Inclusion of this study in the
meta-analysis resulted in a P-value of 0.04 for the
Breslow–Day test, suggesting significant heterogeneity
between the studies. In view of the heterogeneity, the
meta-analysis was, therefore, restricted to cohorts of
Northern European descent and the results from the
Brazilian cohort were not included in the calculation of
the pooled OR. The pooled OR for the UK, US and
Norwegian studies (Breslow–Day P¼0.74) was 0.82 95%
CI: 0.73–0.93, P¼0.001. The combined analysis had a
slightly more significant P-value and tighter CIs than
that found for our UK JIA study alone (Figure 1).
Discussion
The results from this investigation and the meta-analysis
of previous studies suggest that the CCR5D32 variant is
associated with protection from developing JIA for
individuals of Northern European descent. Our study
was the largest to date to investigate this association and
had 480% power to detect a protective OR of p0.75,
similar to the effect size identified in the Prahalad meta-
analysis for RA (OR¼0.65).
13 The meta-analysis high-
lights the need for large sample sizes to detect variants
with a modest effect.
The US family-based association study of the CCR5D32
variant found no significant deviation of transmission of
CCR5D32 in the combined cohort of probands with JIA.
However, stratification by age at onset found that
CCR5D32 was significantly undertransmitted to pro-
bands with early-onset JIA (o6 years). In the UK cohort,
there was no evidence for a stronger effect in cases with a
young age at onset (Ptrend¼0.1, OR 0.83 95% CI: 0.66–
1.04); in fact, those with an older age at onset showed a
slightly stronger effect (Ptrend¼0.03, OR 0.77 95% CI:
0.60–0.97).
The same protective association has been found in RA
but, as with JIA, there have been some conflicting results;
however, a meta-analysis of five case–control association
studies confirmed the protective association between
CCR5D32 and RA (OR 0.65 95% CI: 0.55–0.77, Po0.0001).
This is further evidence for shared susceptibility loci for
RA and JIA, and adds to the evidence from other loci,
which are associated with both diseases (and often other
autoimmune diseases as well), such as PTPN22, IL2/IL21
region, IL2RA, AFF3, STAT4, TRAF1/C5 and TNFAIP3.
17–19
Indeed, the CCR5D32 variant has previously been
associated with protection from developing both type I
diabetes and celiac disease,
20 suggesting a pan-autoim-
mune disease role.
The influence of CCR5D32 on the clinical course of RA
has also been investigated, but again the evidence is
Table 1 Association analysis of the CCR5D32 variant in UK JIA cases and controls
Variant CHR Position Minor
allele
Major
allele
MAF
cases
MAF
controls
Case 11
(%)
Case 12
(%)
Case 22
(%)
Control 11
(%)
Control 12
(%)
Control 22
(%)
Ptrend OR
(95% CI)
CCR5D32
(rs333)
3 46414947 T G 0.09 0.11 6 (0.6) 169 (17.2) 808 (82.2) 35 (1.1) 642 (20.6) 2444 (78.3) 0.006 0.79 (0.66–0.94)
Abbreviations: CHR, chromosome; CI, confidence interval; JIA, juvenile idiopathic arthritis; MAF, minor allele frequency; OR, odds ratio.
Table 2 JIA ILAR subtype stratification analysis
JIA ILAR subtype MAF
cases
MAF
controls
Ptrend OR 95% CI
Systemic onset JIA 0.12 0.11 0.94 1.01 0.71–1.45
Persistent oligoarthritis 0.09 0.11 0.1 0.78 0.57–1.06
Extended oligoarthritis 0.09 0.11 0.2 0.76 0.49–1.16
RF-negative polyarthritis 0.11 0.11 0.63 0.92 0.66–1.29
RF-positive polyarthritis 0.05 0.11 0.03 0.41 0.18–0.93
Enthesitis-related arthritis 0.11 0.11 0.79 0.93 0.52–1.66
Psoriatic arthritis 0.06 0.11 0.06 0.53 0.27–1.04
Abbreviations: CI, confidence interval; MAF, minor allele frequency;
OR, odds ratio; RF, rheumatoid factor.
Association of the CCR5 gene with JIA
A Hinks et al
585
Genes and Immunityoften conflicting, with the most recent study finding that
carriers of the deletion were protected from joint erosion,
had less extra-articular manifestations and had lower
cumulative C-reactive protein levels.
21 However, a number
of other studies have found no evidence for an association
with disease severity or outcome.
10,22,23 These discrepan-
cies may arise as a result of differences in statistical power
and methodologies used but, given the fact that CCR5
expression levels may be associated with severity, it would
be interesting to investigate whether CCR5D32 has any
effect on outcome in JIA. Data from the CAPS (Childhood
Arthritis Prospective Study), a prospective inception
cohort study of JIA cases, will be invaluable in exploring
this hypothesis, but are insufficiently powered at present
to undertake these investigations.
The observation that there are six JIA cases that are
homozygous for CCR5D32 suggests that there may be
some redundancy in the chemokine system and other
receptors and ligands may have a role in the development
of JIA. A previous study that found high expression of
two chemokine receptors, CCR5 and CXCR3 on SF on
T cells from 20 JIA patients compared with peripheral
blood Tcells also found some evidence of redundancy.
2 In
that study, one of the JIA patients was homozygous for
CCR5D32 but was, perhaps surprisingly, of the more
severe extended oligoarthritis subtype. This individual
had high levels of CXCR3 on SF T cells and had a high
interferon-g:IL4 ratio in the cytokine stimulation assay. In
most cases, SF Tcells were double positive for CCR5 and
CXCR3, but T cells can express one or the other. The
different coexpression also suggests that the levels of
these two receptors are regulated by different factors.
It has been proposed that CCR5 is important in the
recruitment of Th1 T cells to the joint but also,
interestingly, a number of studies have linked CCR5 to
the IL2 pathway. For example, IL2 upregulates CCR5
expression in vivo and in vitro
24–26 and rapamycin, a drug
that disrupts IL2 receptor signaling, reduces CCR5
surface expression on T cells.
27 A recent study found
that CCR5D32/D32 donors of peripheral blood mono-
nuclear cells stimulated by antiCD3/CD28 showed
significantly less IL2 production than did noncarriers of
the CCR5D32 mutation. They showed that CCR5 influ-
enced IL2 transcript levels and also that CCR5 influenced
the expression of IL2RA/CD25 on CD4þ T cells both
in vitro and in vivo. There was evidence that these effects
are mediated through the nuclear factor of activated Tcell
signaling pathway. CCR5 expression was also shown
Table 3 Allele frequencies in patients with JIA and healthy controls for the CCR5D32 variant
Author (references) Country Subjects JIA Subjects Controls OR (95% CI)
CCR5-WT N (%) CCR5D32 N (%) CCR5-WT N CCR5D32 N (%)
Prahalad et al.
14 United States 833 1519 (91.2) 147 (8.8) 1708
a 3076 (90.0) 340 (10.0) 0.88 (0.72–1.07)
Lindner et al.
15 Norway 515 931 (90.4) 99 (9.7) 645 1142 (88.5) 148 (11.5) 0.82 (0.63–1.08)
Hinks et al.
17 United Kingdom 983 1785 (90.8) 181 (9.2) 3121 5530 (88.6) 712 (11.4) 0.79 (0.66–0.93)
Schiebel et al.
16b Brazil 101 183 (90.6) 19 (9.4) 104 200 (96.2) 8 (3.8) 2.6 (1.1–6.07)
Abbreviations: CI, confidence interval; JIA, juvenile idiopathic arthritis; OR, odds ratio.
aControls are parents and unaffected siblings of the probands.
bNot included in the meta-analysis.
Figure 1 Meta-analysis of three studies of the CCR5D32 variant. Meta-analysis of UK, US and Norwegian JIA cohorts for the CCR5 gene. Forest
plot displaying odds ratios and 95% confidence intervals for each of the studies and the weighting for each study according to sample size. The
combined OR from the three studies is displayed as a diamond with the peaks denoting the upper and lower limits of the confidence intervals.
Values below 1 depict a negative (protective) association. The Breslow-Day test was performed to test for heterogeneity between the two studies,
with a significant P-value suggesting heterogeneity between studies. The combined P-value is displayed below the heterogeneity P-value.
Association of the CCR5 gene with JIA
A Hinks et al
586
Genes and Immunityto promote T-cell proliferation after T-cell activation.
28
This is fascinating in that the IL2 gene region
19,29 and
IL2RA genes
30 are also associated with JIA. Interestingly,
in all three cases, the SNP in the gene/region is
associated with protection from JIA.
In conclusion, we have presented evidence for a
protective association of the CCR5D32 variant in an UK
JIA case–control cohort, which is strengthened by
combining data obtained from two previous studies in
populations of Northern European descent by meta-
analysis. Further investigation into how this gene
contributes to JIA pathogenesis is now required.
Materials and methods
Subjects
DNA was available for 1054 UK Caucasian JIA patients
(332 males and 715 females) from three sources: BSPAR
(The British Society for Paediatric and Adolescent
Rheumatology) National Repository of JIA (n¼654);
a group of UK Caucasian patients with long-standing
JIA (n¼201), described previously;
31 and a third cohort
collected as part of the CAPS, a prospective inception
cohort study of JIA cases from five centers across the
United Kingdom (n¼199).
32 JIA cases were classified
according to the ILAR criteria
33 (Supplementary Table 1).
Healthy Caucasian control DNA samples (n¼3129) were
available from five centers in the United Kingdom as
described previously:
34 Manchester, Sheffield, Leeds,
Aberdeen and Oxford (total control sample size after
quality control¼3121). All individuals were recruited
with ethical approval and provided informed consent
(North-west Multi-Centre Research Ethics Committee
(MREC 99/8/84) and the University of Manchester
Committee on the Ethics of Research on Human Beings).
Genotyping
The CCR5D32 variant (rs333) was genotyped using the
Sequenom iPlex MassARRAY platform according to
the manufacturer’s instructions (Sequenom, San Diego,
CA, USA; http://www.sequenom.com/). A 90% sample
quality control rate and a 90% genotyping success rate
were imposed on the analysis.
Statistical analysis
Power calculations were performed using QUANTO to
calculate the prior probability of detecting association in
the current sample size at the allele frequency and effect
sizes were reported previously in other autoimmune
diseases for this variant.
14 Calculations assumed a log-
additive model, an a value of 0.05 and an effect size of
0.75. Genotype and allele frequencies were compared
between cases with JIA and controls using the Cochrane–
Armitage trend test implemented in PLINK (http://pngu.
mgh.harvard.edu/purcell/plink/),
35 and allelic ORs and
their 95% CIs were calculated. JIA is a phenotypically
heterogeneous disease and can be classified into more
clinically homogeneous diseases using the ILAR classifi-
cation criteria.
36 However, comparing each of the ILAR
subtypes separately against controls would result in a
large number of hypothesis tests. Therefore, we also
examined whether there was evidence of a difference in
allele frequencies between the seven ILAR subtypes.
Differences between subtypes were assessed using w
2-
tests on the 7 2t a b l e s .
Published case–control association studies of CCR5D32
with JIA were identified using a PUBMED search.
Genotype and allele frequencies were obtained from
the published studies. A test for heterogeneity between
cohorts was carried out using the Breslow–Day test, and
the Cochran–Mantel–Haenszel test was used to perform
a meta-analysis of the three cohorts.
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